FBRX — Forte Biosciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1419041 ·
Last close
$21.94
Market Cap
$449.31M
52W High
$35.80
52W Low
$19.03
ADV30
227,610
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -22,439,000 | -22,136,000 | 67,223,000 | 58,223,000 | 25,123,000 |
| Dec 2025 | 0 | — | -24,571,000 | -24,788,000 | 82,779,000 | 76,957,000 | 21,788,000 |
| Sep 2025 | 0 | — | -18,383,000 | -17,682,000 | 97,089,000 | 93,414,000 | 12,992,000 |
| Jun 2025 | 0 | — | -11,579,000 | -11,249,000 | 107,783,000 | 106,144,000 | 9,170,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-50,882,000
Investing CF
$36,234,000
Financing CF
$69,361,000
CapEx
$-147,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-7.86
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-223,373,000
Inventory
—
Receivables
$817,000
ST Investments
$0
EBIT TTM
$-70,657,000
Pretax Income TTM
$-68,338,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -70,657,000 | -69,375,000 | 82,779,000 | 21,788,000 | — | -50,882,000 |
| Dec 2024 | 0 | -36,602,000 | -35,478,000 | 61,561,000 | 9,081,000 | — | -30,745,000 |
| Dec 2023 | 0 | -32,486,000 | -31,476,000 | 38,980,000 | 3,666,000 | — | -28,706,000 |
| Dec 2022 | 0 | -13,896,000 | -13,879,000 | 41,997,000 | 3,179,000 | — | -8,185,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.14
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTNM | Contineum Therapeutics, Inc. | $448.32M | $13.70 | — |
| FULC | Fulcrum Therapeutics, Inc. | $450.44M | $6.76 | — |
| UPB | Upstream Bio, Inc. | $446.79M | $8.21 | — |
| ADCT | ADC Therapeutics SA | $446.44M | $3.51 | — |
| ASMB | ASSEMBLY BIOSCIENCES, INC. | $456.91M | $28.75 | — |
News headlines (Yahoo Finance, 1h cache)
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
2026-05-11 20:01 · Yahoo
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update
2026-05-11 13:01 · Yahoo
Top Midday Gainers
2026-04-09 18:05 · Yahoo
Forte Biosciences Announces Pricing of $150 Million Public Offering
2026-04-09 01:30 · Yahoo
Forte Biosciences Announces Proposed Public Offering
2026-04-08 20:02 · Yahoo
Forte Biosciences, Inc. Announces 2025 Results and Provides Update
2026-03-31 20:01 · Yahoo
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
2026-03-17 20:01 · Yahoo
Forte Biosciences (FBRX) Upgraded to Buy: Here's What You Should Know
2026-02-25 17:00 · Yahoo
We Think Forte Biosciences (NASDAQ:FBRX) Can Afford To Drive Business Growth
2026-02-18 11:22 · Yahoo
Forte Biosciences, Inc. to Present at Upcoming Investor Meetings
2026-02-09 21:01 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.